David Moatazedi Sells 111,323 Shares of Evolus, Inc. (NASDAQ:EOLS) Stock

Evolus, Inc. (NASDAQ:EOLS - Get Free Report) insider David Moatazedi sold 111,323 shares of the firm's stock in a transaction on Friday, June 13th. The stock was sold at an average price of $10.05, for a total transaction of $1,118,796.15. Following the transaction, the insider now directly owns 381,509 shares in the company, valued at $3,834,165.45. The trade was a 22.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

David Moatazedi also recently made the following trade(s):

• On Monday, June 16th, David Moatazedi sold 16,582 shares of Evolus stock. The stock was sold at an average price of $9.89, for a total transaction of $163,995.98.
• On Monday, May 12th, David Moatazedi sold 15,787 shares of Evolus stock. The shares were sold at an average price of $9.87, for a total value of $155,817.69.
• On Thursday, March 27th, David Moatazedi sold 6,251 shares of Evolus stock. The shares were sold at an average price of $12.40, for a total transaction of $77,512.40.

Evolus Stock Down 7.1%

Shares of NASDAQ EOLS traded down $0.71 during trading on Tuesday, hitting $9.25. The company had a trading volume of 2,184,578 shares, compared to its average volume of 748,878. Evolus, Inc. has a 52 week low of $8.67 and a 52 week high of $17.82. The business's 50-day moving average is $10.32 and its 200 day moving average is $11.75. The company has a debt-to-equity ratio of 22.00, a current ratio of 2.34 and a quick ratio of 2.16.

Institutional Investors Weigh In On Evolus

Institutional investors and hedge funds have recently modified their holdings of the stock. Principal Financial Group Inc. raised its holdings in Evolus by 9.8% during the 4th quarter. Principal Financial Group Inc. now owns 33,370 shares of the company's stock worth $368,000 after buying an additional 2,989 shares during the period. Barclays PLC raised its holdings in shares of Evolus by 12.9% during the fourth quarter. Barclays PLC now owns 105,786 shares of the company's stock valued at $1,167,000 after acquiring an additional 12,124 shares during the period. Frontier Capital Management Co. LLC acquired a new stake in shares of Evolus during the fourth quarter valued at approximately $2,648,000. Raymond James Financial Inc. purchased a new stake in shares of Evolus in the 4th quarter valued at approximately $575,000. Finally, Comerica Bank acquired a new position in Evolus in the 4th quarter worth approximately $312,000. 90.69% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. BTIG Research assumed coverage on shares of Evolus in a report on Thursday, April 17th. They set a "buy" rating and a $21.00 price target for the company. HC Wainwright reiterated a "buy" rating and issued a $27.00 price objective on shares of Evolus in a research report on Thursday, April 10th. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 target price on shares of Evolus in a research report on Thursday, May 8th. Finally, Barclays upped their price objective on Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $23.75.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.